get a key
steadybase-$ person Michael Donegan
nameMichael Donegan
roleCFO
company TherapeuticsMD Inc. TXMD
linkedin none on file
contactnot published
filingsnone on file
quotes
Selling and marketing costs were $23.7 million for the second quarter, a decrease of $8.5 million for 26.4% compared to the second quarter of 2021 due to lower brand spending for Invexi and Overa, reduced compensation and employee benefit expense, and lower consulting expenditures, partially offset by higher education, conference, and software development costs.

Aug 15, 2022 / CFO / receipt, needs a key / Michael Donegan, CFO | earnings call 2022-08-15 | transcript 9308a1fd-2990-46dc-8378-1b5fabcfcff5 | chars 6461-6825 | segment 6

steadybase-$